$NBIX
NEUROCRINE BIOSCIENCES INC

2019 Q4 Form 10-K Financial Statement

#000156459020003773 Filed on February 07, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2018 Q4 2018 Q3
Revenue $244.1M $131.5M $151.8M
YoY Change 85.64% 39.12% 149.71%
Cost Of Revenue $2.500M $1.500M $1.600M
YoY Change 66.67% 87.5% 269.52%
Gross Profit $241.5M $130.0M $150.2M
YoY Change 85.77% 38.59% 148.92%
Gross Profit Margin 98.93% 98.87% 98.97%
Selling, General & Admin $101.2M $69.00M $60.40M
YoY Change 46.67% 22.56% 37.67%
% of Gross Profit 41.9% 53.08% 40.21%
Research & Development $55.40M $39.10M $35.48M
YoY Change 41.69% 52.73% 57.96%
% of Gross Profit 22.94% 30.08% 23.62%
Depreciation & Amortization $2.100M $1.300M $1.000M
YoY Change 61.54% 85.71% 66.67%
% of Gross Profit 0.87% 1.0% 0.67%
Operating Expenses $195.3M $109.6M $97.43M
YoY Change 78.16% 32.58% 45.93%
Operating Profit $46.20M $20.38M $54.32M
YoY Change 126.7% 83.31% -1006.14%
Interest Expense -$10.10M -$3.100M $7.672M
YoY Change 225.81% -39.22% 4.57%
% of Operating Profit -21.86% -15.21% 14.12%
Other Income/Expense, Net -$3.559M
YoY Change -30.62%
Pretax Income $38.60M $18.80M $50.76M
YoY Change 105.32% 172.46% -557.33%
Income Tax $4.600M $700.0K
% Of Pretax Income 11.92% 3.72%
Net Earnings $34.00M $18.08M $50.76M
YoY Change 88.07% 162.23% -556.31%
Net Earnings / Revenue 13.93% 13.75% 33.45%
Basic Earnings Per Share $0.37 $0.20 $0.56
Diluted Earnings Per Share $0.35 $0.19 $0.52
COMMON SHARES
Basic Shares Outstanding 92.20M shares 90.74M 90.56M
Diluted Shares Outstanding 97.20M shares 95.72M 96.80M

Balance Sheet

Concept 2019 Q4 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $670.5M $650.9M $635.3M
YoY Change 3.01% 26.16% 24.32%
Cash & Equivalents $112.3M $141.7M $201.2M
Short-Term Investments $558.2M $509.2M $439.6M
Other Short-Term Assets $16.60M $18.59M $18.90M
YoY Change -10.72% 171.88% 155.16%
Inventory $17.30M $10.86M $6.100M
Prepaid Expenses
Receivables $126.6M $57.41M $54.10M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $831.0M $737.8M $714.4M
YoY Change 12.64% 32.95% 30.25%
LONG-TERM ASSETS
Property, Plant & Equipment $41.90M $33.87M $28.62M
YoY Change 23.71% 213.28% 213.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $355.5M $216.0M $185.3M
YoY Change 64.58% -12.69% -11.89%
Other Assets $0.00 $5.500M $5.500M
YoY Change -100.0% 22.22% 19.57%
Total Long-Term Assets $475.0M $255.4M $219.3M
YoY Change 86.0% -2.78% -2.08%
TOTAL ASSETS
Total Short-Term Assets $831.0M $737.8M $714.4M
Total Long-Term Assets $475.0M $255.4M $219.3M
Total Assets $1.306B $993.2M $933.7M
YoY Change 31.5% 21.47% 20.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $141.3M $13.80M $72.00M
YoY Change 923.84% 144.35% 93.03%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $408.8M $0.00 $383.6M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $565.3M $88.23M $456.4M
YoY Change 540.69% 62.12% 1096.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $388.5M $0.00
YoY Change -100.0% 5.11% -100.0%
Other Long-Term Liabilities $17.10M $35.66M $29.80M
YoY Change -52.04% 26271.68%
Total Long-Term Liabilities $17.10M $35.66M $29.80M
YoY Change -52.04% 26271.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $565.3M $88.23M $456.4M
Total Long-Term Liabilities $17.10M $35.66M $29.80M
Total Liabilities $669.1M $512.4M $486.2M
YoY Change 30.59% 15.03% 14.41%
SHAREHOLDERS EQUITY
Retained Earnings -$1.133B -$1.178B -$1.196B
YoY Change -3.83% -1.76% -0.82%
Common Stock $1.768B $1.660B $1.645B
YoY Change 6.49% 5.57% 5.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $636.9M $480.8M $447.5M
YoY Change
Total Liabilities & Shareholders Equity $1.306B $993.2M $933.7M
YoY Change 31.5% 21.47% 20.87%

Cashflow Statement

Concept 2019 Q4 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income $34.00M $18.08M $50.76M
YoY Change 88.07% 162.23% -556.31%
Depreciation, Depletion And Amortization $2.100M $1.300M $1.000M
YoY Change 61.54% 85.71% 66.67%
Cash From Operating Activities $102.6M $50.50M $68.90M
YoY Change 103.17% 24.38% -840.86%
INVESTING ACTIVITIES
Capital Expenditures -$2.800M -$6.000M -$12.40M
YoY Change -53.33% 160.87% 342.86%
Acquisitions
YoY Change
Other Investing Activities -$163.3M -$100.2M -$32.80M
YoY Change 62.97% 74.87% 0.61%
Cash From Investing Activities -$166.2M -$106.2M -$45.10M
YoY Change 56.5% 77.89% 27.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.300M 1.800M 5.400M
YoY Change 305.56% -67.86% 80.0%
NET CHANGE
Cash From Operating Activities 102.6M 50.50M 68.90M
Cash From Investing Activities -166.2M -106.2M -45.10M
Cash From Financing Activities 7.300M 1.800M 5.400M
Net Change In Cash -56.30M -53.90M 29.20M
YoY Change 4.45% 299.26% -170.02%
FREE CASH FLOW
Cash From Operating Activities $102.6M $50.50M $68.90M
Capital Expenditures -$2.800M -$6.000M -$12.40M
Free Cash Flow $105.4M $56.50M $81.30M
YoY Change 86.55% 31.7% -1350.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
0-22705
CY2019 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES, INC.
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0525145
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
12780 El Camino Real
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
92292392
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1306040000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
161626000
CY2019 nbix Research And Development Expense Excluding Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
200042000
CY2019 nbix Cost Of Sales
CostOfSales
7428000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
92000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1768118000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1413000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1132700000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
636923000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
451240000
CY2018 nbix Cost Of Sales
CostOfSales
4889000
CY2019 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
19209000
CY2018 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
15476000
CY2017 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
8342000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25741000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15054000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11181000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21841000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-142542000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-142542000
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2017 nbix Cost Of Sales
CostOfSales
1254000
CY2017 nbix Research And Development Expense Excluding Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
91827000
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
248932000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
169906000
CY2017 us-gaap Operating Expenses
OperatingExpenses
292987000
CY2019 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2019 dei Trading Symbol
TradingSymbol
NBIX
CY2019 dei City Area Code
CityAreaCode
858
CY2019 dei Local Phone Number
LocalPhoneNumber
617-7600
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019Q4 us-gaap Assets Current
AssetsCurrent
831034000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
737777000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
299654000
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
216028000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
74364000
CY2019Q4 us-gaap Equity Securities Fv Ni Restricted
EquitySecuritiesFvNiRestricted
55868000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41914000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33869000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3206000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5477000
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q2 dei Entity Public Float
EntityPublicFloat
5752910928
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112279000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141714000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
558245000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
509199000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
126575000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
57406000
CY2019Q4 us-gaap Inventory Net
InventoryNet
17288000
CY2018Q4 us-gaap Inventory Net
InventoryNet
10864000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
16647000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18594000
CY2019Q4 us-gaap Assets
Assets
1306040000
CY2018Q4 us-gaap Assets
Assets
993151000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
141285000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
86377000
CY2019Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
408807000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15195000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1856000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
565287000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
88233000
CY2018Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
388496000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
86756000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17074000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35657000
CY2019Q4 us-gaap Liabilities
Liabilities
669117000
CY2018Q4 us-gaap Liabilities
Liabilities
512386000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000
CY2018 us-gaap Interest Expense
InterestExpense
30530000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9530000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92272000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92272000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90797000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90797000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
91000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1660361000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1932000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1177755000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
480765000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
993151000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
788087000
CY2018 nbix Research And Development Expense Excluding Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
155774000
CY2019 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
154272000
CY2018 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
4750000
CY2017 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
30000000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
354062000
CY2019 us-gaap Operating Expenses
OperatingExpenses
715804000
CY2018 us-gaap Operating Expenses
OperatingExpenses
414345000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
72283000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
36895000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-131361000
CY2019 us-gaap Interest Expense
InterestExpense
31963000
CY2017 us-gaap Interest Expense
InterestExpense
19523000
CY2019 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-12987000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
46542000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
730000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
37012000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
21111000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.62
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.62
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91627000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90235000
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88089000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95732000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95386000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88089000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
314877000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-142542000
CY2017 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1532000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42522000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000
CY2017 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
144948000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
372138000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
21111000
CY2018 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-82000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58068000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29530000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
480765000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
37012000
CY2019 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
3345000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75262000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27313000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5183000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
636923000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
37012000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
21111000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-142542000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
75262000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
58068000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
42522000
CY2019 us-gaap Depreciation
Depreciation
7452000
CY2018 us-gaap Depreciation
Depreciation
4024000
CY2017 us-gaap Depreciation
Depreciation
2400000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
18922000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
17552000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10937000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1389000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1326000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
848000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1965000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1449000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1756000
CY2019 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-12987000
CY2018 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
0
CY2017 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
0
CY2019 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
754000
CY2018 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-409000
CY2017 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-1445000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
69169000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25113000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
31127000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6424000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3524000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1024000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
53955000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24223000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
27338000
CY2019 us-gaap Increase Decrease In Other Current Assets And Liabilities Net
IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
-21879000
CY2018 us-gaap Increase Decrease In Other Current Assets And Liabilities Net
IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
-2657000
CY2017 us-gaap Increase Decrease In Other Current Assets And Liabilities Net
IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
3994000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
152054000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
101364000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-94331000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
797169000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
545962000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
583408000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
669691000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
327825000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
339088000
CY2019 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
68855000
CY2018 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
CY2017 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14748000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24812000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6940000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
953000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
11644000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
6242000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2318000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
34000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-211073000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-242915000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-251253000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27313000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29530000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13865000
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
502781000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27313000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29530000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
516646000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31706000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-112021000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
171062000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147191000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259212000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88150000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115485000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147191000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259212000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
11644000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
507000
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates.<span style="font-weight:normal;font-style:normal;"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></p>
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7855000
CY2019 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
0
CY2018 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
0
CY2018Q4 nbix Fair Value Transfers Between Levels
FairValueTransfersBetweenLevels
0
CY2019Q4 nbix Fair Value Transfers Between Levels
FairValueTransfersBetweenLevels
0
CY2019 us-gaap Depreciation
Depreciation
7500000
CY2018 us-gaap Depreciation
Depreciation
4000000.0
CY2017 us-gaap Depreciation
Depreciation
2400000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
120678000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk. <span style="font-weight:normal;font-style:normal;">We do not currently have any of our own manufacturing facilities and therefore we depend on an outsourced manufacturing strategy for the production of INGREZZA for commercial use and for the production of our product candidates in clinical trials. We have contracts with one third-party manufacturer approved for the commercial production of </span></p> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-style:normal;">INGREZZA’s capsules at </span><span style="font-weight:normal;font-style:normal;">two</span><span style="font-weight:normal;font-style:normal;"> separate sites and </span><span style="font-weight:normal;font-style:normal;">two</span><span style="font-weight:normal;font-style:normal;"> </span><span style="font-weight:normal;font-style:normal;">third-party manufacturer</span><span style="font-weight:normal;font-style:normal;">s</span><span style="font-weight:normal;font-style:normal;"> approved for the production of INGREZZA’s </span><span style="font-weight:normal;font-style:normal;">API</span><span style="font-weight:normal;font-style:normal;">. Although there are potential sources of supply other than </span><span style="font-weight:normal;font-style:normal;">our</span><span style="font-weight:normal;font-style:normal;"> existing suppliers, any new supplier would be required to qualify under applicable regulatory requirements.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into distribution agreements with a limited number of specialty pharmacy providers and a specialty distributor, and all of our product sales are to these customers. Our two largest customers represented approximately 86% of our product revenue for 2019 and a significant majority of our accounts receivable balance at December 31, 2019. For 2018 and 2017, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018 and 2017.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivables. We established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and placing investments with maturities that maintain safety and liquidity.</p>
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
408807000
CY2018Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
388496000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1470000
CY2019Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
517500000
CY2018Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
517500000
CY2019Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6937000
CY2018Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
8326000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
101756000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
725227000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14148000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
346000000.0
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2208000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1670000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
801000
CY2019Q4 us-gaap Inventory Net
InventoryNet
17288000
CY2018Q4 us-gaap Inventory Net
InventoryNet
10864000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
75473000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
62140000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33559000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28271000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41914000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33869000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
38941000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27341000
CY2019Q4 nbix Revenue Related Reserves For Discounts And Allowances
RevenueRelatedReservesForDiscountsAndAllowances
30634000
CY2018Q4 nbix Revenue Related Reserves For Discounts And Allowances
RevenueRelatedReservesForDiscountsAndAllowances
13586000
CY2019Q4 nbix Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
25496000
CY2018Q4 nbix Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7069000
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
46214000
CY2018Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
38381000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
141285000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
86377000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112279000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
335200000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141714000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3206000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5477000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
115485000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
147191000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
37012000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
21111000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-142542000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91627000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90235000
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88089000
CY2019 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1072000
CY2018 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1348000
CY2017 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95732000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95386000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88089000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.62
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.62
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75262000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.83
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4000000.0
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
181300000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
268200000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6356000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
41.74
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5746000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.01
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1416000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
46.55
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
983000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.41
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
72000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
43.05
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6107000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.62
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
41.38
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
41.01
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
64300000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
117000000.0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
61400000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
335700000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27300000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29500000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13900000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9530000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
730000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
433000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
9775000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
4587000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-49889000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
4044000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
361000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4013000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
855000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
446000
CY2019 nbix Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee
IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee
3707000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-12785000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-9778000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-19589000
CY2019 nbix Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
3068000
CY2018 nbix Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
915000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-100000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
9530000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
830000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
9530000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
730000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 nbix Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
2163000
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-4143000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-198000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
154415000
CY2019 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
1228000
CY2018 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
13874000
CY2017 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
2998000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
10359000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
13526000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
335200000
CY2019 nbix Percentage Of Uncertain Tax Positions Likelihood Of Being Sustained
PercentageOfUncertainTaxPositionsLikelihoodOfBeingSustained
0.50
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
5596000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13883000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4306000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-79966000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
257000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-257000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-956000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
57900000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000.0
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000.0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
223800000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
71900000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
62200000
CY2019Q4 nbix Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
28000000
CY2018Q4 nbix Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
34800000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
22900000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
17300000
CY2019Q4 nbix Deferred Tax Assets Operating Leases Assets
DeferredTaxAssetsOperatingLeasesAssets
23300000
CY2018Q4 nbix Deferred Tax Assets Operating Leases Assets
DeferredTaxAssetsOperatingLeasesAssets
100000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
49300000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
9400000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
18500000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
19100000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
395200000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
366700000
CY2019Q4 nbix Deferred Tax Liabilities Convertible Senior Notes
DeferredTaxLiabilitiesConvertibleSeniorNotes
24100000
CY2018Q4 nbix Deferred Tax Liabilities Convertible Senior Notes
DeferredTaxLiabilitiesConvertibleSeniorNotes
26400000
CY2019Q4 nbix Deferred Tax Liabilities Operating Leases Liabilities
DeferredTaxLiabilitiesOperatingLeasesLiabilities
18200000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
6900000
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
5100000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
49200000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31500000
CY2019Q4 nbix Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
346000000
CY2018Q4 nbix Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
335200000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
346000000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
37403000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
34112000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
281000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
6103000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
9519000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
11726000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3291000
CY2019 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
657000
CY2018 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
457000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
63918000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
54775000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
37403000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
9500000
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2018Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
8000000.0
CY2019 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
1
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2
CY2007Q4 nbix Number Of Vacated Buildings
NumberOfVacatedBuildings
1
CY2019Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12Y
CY2019Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The 2019 amendment includes two options to extend the term of the lease for a period of ten years each. We were not reasonably certain to exercise either of these options at lease commencement.
CY2019Q3 nbix Number Of Renewal Options
NumberOfRenewalOptions
2
CY2019Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P10Y
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
8100000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
7700000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
74400000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
95000000.0
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y2M12D
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8558000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10578000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10900000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11232000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
11574000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
91271000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
134681000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
39643000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
95038000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8282000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
86756000
CY2019Q4 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced
28300000
CY2019 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.60
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
4900000
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1800000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1100000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
138403000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
183580000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
222094000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
244010000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
239400000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
149119000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
131996000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
195289000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-102115000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
51338000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
53789000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
34000000
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.59
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.56
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91056000
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91389000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91859000
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92182000
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91056000
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94779000
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96074000
CY2019Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97229000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
71086000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
96905000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
151757000
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
131492000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
108533000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
98757000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
97434000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
109621000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-41818000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5913000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
50764000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
18078000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89526000
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90100000
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90555000
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90742000
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89526000
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90100000
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96798000
CY2018Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95724000

Files In Submission

Name View Source Status
0001564590-20-003773-index-headers.html Edgar Link pending
0001564590-20-003773-index.html Edgar Link pending
0001564590-20-003773.txt Edgar Link pending
0001564590-20-003773-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gvpzij23bxbs000001.jpg Edgar Link pending
gvpzij23bxbs000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nbix-10k_20191231.htm Edgar Link pending
nbix-10k_20191231_htm.xml Edgar Link completed
nbix-20191231.xsd Edgar Link pending
nbix-20191231_cal.xml Edgar Link unprocessable
nbix-20191231_def.xml Edgar Link unprocessable
nbix-20191231_lab.xml Edgar Link unprocessable
nbix-20191231_pre.xml Edgar Link unprocessable
nbix-ex1016_75.htm Edgar Link pending
nbix-ex211_11.htm Edgar Link pending
nbix-ex231_323.htm Edgar Link pending
nbix-ex311_8.htm Edgar Link pending
nbix-ex312_12.htm Edgar Link pending
nbix-ex32_13.htm Edgar Link pending
nbix-ex44_74.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending